



**Resonance Health Ltd ASX / Media Release** 

27 November 2014

## **RESULTS OF RESOLUTIONS AT ANNUAL GENERAL MEETING**

The resolutions put to Members at the Annual General Meeting held today, 27<sup>th</sup> November 2014, were passed on a show of hands. In accordance with the Corporations Act we advise that proxy votes were received as follows:

|   | For         | Against   | Abstain    | Proxy<br>Discretion | Total       |
|---|-------------|-----------|------------|---------------------|-------------|
|   |             |           |            |                     |             |
| Resolution 1<br>Remuneration<br>Report                    | 31,488,418  | 1,532,573 | 73,480,734 | 205,226             | 106,706,951 |
| Resolution 2<br>Re-election of Director<br>– Simon Panton | 105,950,167 | 550,000   | 1,558      | 205,226             | 106,706,951 |
| Resolution 3<br>Adoption of Employee<br>Share Plan        | 101,590,412 | 4,916,005 | 1,558      | 198,976             | 106,706,951 |

For further information please contact:

**Resonance Health** 

Adrian Bowers **Company Secretary** T: +61 8 9286 5300 E:adrianb@resonancehealth.com Liza Dunne Managing Director T: +61 8 9286 5300 E: lizad@resonancehealth.com

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a medical device company providing imaging core laboratory services for the quantitative analysis of MR medical images, with a subspecialty in the liver. Resonance Health's patented FerriScan technology provides a safe and accurate alternative for measuring liver iron concentration. HepaFat-Scan is FDA cleared for the measurement of liver fat and research continues into the development of new technology for the accurate assessment of liver fibrosis.

Resonance Health Limited ABN: 96 006 762 492